The globalization and increasing complexity of clinical trials have led sponsors to engage multiple specialized service providers—ranging from central laboratories and data managers to imaging and safety vendors—to execute delegated trial activities. Under ICH E6(R3) Good Clinical Practice (GCP), however, delegation does not relieve the sponsor of ultimate responsibility. To fulfil regulatory and ethical obligations, sponsors must implement a robust oversight framework that links service provider management with a cross‑functional, risk‑based quality system focused on Critical to Quality (CtQ) factors. This article outlines practical “to‑dos” for ensuring compliant trial conduct, participant safety, and data integrity.
1. Defining and Documenting Roles
First and foremost, ICH E6(R3) Section 10 mandates that all trial roles and responsibilities be clearly defined and documented. Whether transferring activities to a service provider or delegating functions to an investigator, sponsors retain accountability. Sponsors must ensure comprehensive agreements that:
• Enumerate delegated tasks, deliverables, and timelines;
• Define responsibilities; From my point of view, take the time to meet the teams and make sure to align your expectations. There often are different expectations / interpretations of the same task and responsibility that have the potential to inhibit the flow when two parties are involved sequentially. This is especially important when you outsource partially.
• Detail the GCP and regulatory standards to be met;
• Specify the sponsor’s rights to monitor, audit, and access source data at service provider sites; Take current developments into account and discuss for example the rights to fully access electronic source data.
These agreements form the foundation for subsequent oversight and ensure transparency in the sponsor–provider relationship.
Reference: Section 10, ICH E6(R3)
2. Service Provider Selection and Qualification
A cornerstone of effective oversight is selecting competent service providers. Sponsors must perform a structured qualification process—reviewing SOPs, financial stability, quality metrics, training schedules and regulatory inspection history—to verify that providers can carry out assigned activities.
Are the SOPs shared to allow you to check them? Remember this when your vendors work according to their SOPs.
Selection teams should include representatives from clinical operations, quality assurance, data management, and pharmacovigilance to ensure a cross‑functional perspective on critical processes. Access to performance metrics, audit reports, and relevant certifications is essential for informed decision‑making, as well as handling of sub-contacted vendor handling.
Reference: Sections 3.6.7–3.6.8, ICH E6(R3)
3. Establishing Oversight and Monitoring Measures
Once engaged, service providers must be monitored to confirm GCP compliance. My initial focus here is to engage with involved people and teams to create the base for your collaboration: A space of free communication and trust.
For example: Talk to your CRAs to make sure your trials “specialties” are understood. This is your option to have your sites strongly guided through your study visits.
Key oversight activities include:
• Regular status meetings with documented minutes;
• Periodic performance reviews against agreed KPIs;
• Quality audits tailored to each provider’s risk profile;
• Real‑time tracking of deviations, incidents, and corrective actions.
Agreements should grant sponsors the right to audit and inspect—both on‑site and remotely—and to obtain direct access to source records. Sponsors should also ensure that any subcontracting downstream does not dilute oversight and that providers’ internal quality processes are “fit for purpose” within a GCP context.
Reference: Sections 3.6.4–3.6.6, 3.6.9–3.6.10, ICH E6(R3)
4. Embedding Risk‑Based Quality Management
ICH E6(R3) calls for a proportionate approach to quality driven by CtQ factors—those trial elements that directly impact participant rights, safety, and data reliability. A risk‑based quality management system comprises five integrated steps:
1. Risk Identification:
Map all trial processes—including service provider activities such as data transfers, lab assays, and central imaging analyses—and identify potential hazards that could affect CtQ factors.
2. Risk Evaluation:
Assess the likelihood, detectability, and impact of each risk. For instance, errors in randomization systems could have high impact and low detectability, warranting enhanced controls.
3. Risk Control:
Define and implement mitigation measures—such as redundant data checks, prespecified quality tolerance limits, or additional training—scaled to the importance of each risk.
4. Risk Communication:
Disseminate risk assessments and mitigation plans to cross‑functional stakeholders, including service providers, data managers, clinical operations, and safety teams.
5. Risk Review and Reporting:
Continuously monitor emerging data and periodic performance metrics to validate the effectiveness of controls. Document and report any excursions beyond quality limits, along with remedial actions.
Important: Keep your risk assessment active and continuous. Risks and risk evaluation may change over the course of your trial.
One example of practice: Do not postpone your risk assessment to “the break after submission”. When thoroughly going through your processes and individual study specialties you may find aspects that lead to a protocol amendment.
Reference: Sections 3.10 & 3.9, ICH E6(R3)
5. Oversight Governance and Decision‑Making
Sponsors must tailor oversight measures to the trial’s complexity and risk profile. A governance structure may include:
• Safety Team Meetings: Medical teams to monitor decision impact on safety and data integrity, and protocol deviations classified as “important”.
• Periodic review of key metrics, CtQ trends. Keep in mind that each phase of your clinical trial may come with different risk factors.
• Independent Data Monitoring Committees (IDMCs): For trials with significant safety or efficacy endpoints, IDMCs provide unbiased recommendations on trial continuation.
All trial decisions—ranging from protocol amendments to urgent safety measures—must be risk‑assessed for their impact on participant welfare and data validity and escalated promptly if issues arise.
From my experience, an overview of key decisions and FAQs, continuously updated and made available for your PM, CRAs and Sites adds great value to your portfolio.
Reference: Section 3.9, ICH E6(R3)
6. Cross‑Functional Collaboration and Continuous Improvement
Effective sponsor oversight demands seamless collaboration across functional silos. Clinical operations drive execution, quality assurance verifies compliance, data management tracks metrics, and pharmacovigilance safeguards safety signals. Regular cross‑functional forums enable proactive identification of systemic issues and continuous refinement of oversight strategies.
Conclusion
By integrating rigorous service provider management with a cross‑functional, risk‑based quality management system anchored on Critical to Quality factors, sponsors can fulfil their oversight duties in alignment with ICH E6(R3). That documentation will be expected from regulatory authorities and also enhances trial efficiency, participant protection, and the integrity of data that underpin clinical and regulatory decision‑making: Delegating with oversight empowers responsible outcomes.
